{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:53:33Z","timestamp":1787892813032,"version":"build-2784847793"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41571-025-01113-y","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:07:01Z","timestamp":1765804021000},"page":"155-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer"],"prefix":"10.1038","volume":"23","author":[{"given":"Britt B. M.","family":"Suelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4407-7881","authenticated-orcid":false,"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"1113_CR1","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102\u20132114 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1113_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo, A. B. et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 392, 45\u201355 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1113_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt, J. et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 22, 525\u2013537 (2021).","journal-title":"Lancet Oncol."},{"key":"1113_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","volume":"85","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma. Eur. Urol. 85, 114\u2013122 (2024).","journal-title":"Eur. Urol."},{"key":"1113_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511885","author":"T Powles","year":"2025","unstructured":"Powles, T. et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2511885 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1113_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.139","author":"MD Galsky","year":"2025","unstructured":"Galsky, M. D. et al. Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.139 (2025).","journal-title":"Ann. Oncol."},{"key":"1113_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1113_CR8","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","volume":"393","author":"X Sheng","year":"2025","unstructured":"Sheng, X. et al. Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer. N. Engl. J. Med. 393, 2324\u20132337 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1113_CR9","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1200\/JCO.2025.43.16_suppl.4503","volume":"43","author":"T Powles","year":"2025","unstructured":"Powles, T. et al. Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA. J. Clin. Oncol. 43, 4503 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1113_CR10","doi-asserted-by":"publisher","first-page":"S1763","DOI":"10.1016\/j.annonc.2025.09.124","volume":"36","author":"C Vulsteke","year":"2025","unstructured":"Vulsteke, C. et al. LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study. Ann. Oncol. 36, S1763 (2025).","journal-title":"Ann. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01113-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01113-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01113-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T13:02:22Z","timestamp":1771938142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01113-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1113"],"URL":"https:\/\/doi.org\/10.1038\/s41571-025-01113-y","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"15 December 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.B.M.S declares consultancy roles (on behalf of her institution) for Astellas Pharma Europe, Bristol Myers Squibb, Janssen\u2013Cilag and MSD, and research support (institutional) from Astellas Pharma Europe and Merck. M.S.v.d.H. declares consultancy roles (on behalf of his institution) for Astellas, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen, MSD, Pfizer and SeaGen, and research grant support (institutional) from 4SC, AstraZeneca, Bristol Myers Squibb, MSD and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}